两种方案治疗过敏性结膜炎最小成本分析  

Cost-minimization Analysis of Treatment of Seasonal Allergic Conjunctivitis

作　　者：李康寯[1] 俞阿勇[1] 杨新军[2] 

机构地区：[1]温州医学院附属眼视光医院,浙江温州325000 [2]温州医学院环境与公共卫生学院

出　　处：《药物流行病学杂志》2009年第2期126-128,共3页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:分析两种方案治疗季节性过敏性结膜炎的临床疗效及经济性,指导临床合理用药。方法:66例季节性过敏性结膜炎患者随机分为:Ⅰ组33例(0.1%盐酸奥洛他定)和Ⅱ组33例(0.05%依美斯汀联合0.1%洛度沙胺,33例)治疗后观察疗效,并进行最小成本分析。结果:Ⅰ组和Ⅱ组的治疗总有效率分别为93.94%和90. 91%,两者间差异无显著性(P>0.05);治疗药物成本分别为(154.39±9.65)元和(104.09±3.56)元,两者间差异有显著性(P<0.05)。结论:依美斯汀联合洛度沙胺方案治疗季节性过敏性结膜炎是一种有效、经济的方法。Objective ： To observe the clinical curative and pharmacoeconomic efficacy of the treatment of seasonal allergic conjunctivitis （SAC）. Method： 66 patients with SAC were randomly assigned to receive 0.1% olopatadine （ Group Ⅰ , n =33） and 0.05% emedastine ＋ 0.1% lodoxmamide （Group Ⅱ, n = 33）. The clinical curative effects of the two groups were monitored and the cost minimization analysis was carried out. Result： In the two groups, the total cure rates were 93.94% and 90.91% respectively and both showed no significant differences （P 〉 0.05 ）. The total drug costs were 154.39 ± 9.65 yuan and 104.09 ± 3.56 yuan in the two groups, which showed significant differences（ P 〈 0.05 ）. Conclusion： The therapy of 0.05% emedastine with 0.1% lodoxmamide is superior to 0.1% olopatadine in pharmacoeconomic efficacy in the treatment of SAC.

关 键 词：结膜炎 季节性过敏性 最小成本分析 奥洛他定 

分 类 号：F407.7[经济管理—产业经济]